- Diagnos Inc. (ADK) is launching the testing phase for autonomous artificial intelligence solutions dedicated to diabetic retinopathy screening
- The Quebec-based company is working in partnership with the Centre hospitalier de l’Université de Montréal (CHUM)
- This marks the final step of the partnership, which began in 2018
- Retinal images of more than 600 diabetic patients from the CHUM’s endocrinology department will be analyzed during the study
- The hope is to eventually be able to reduce complications that can lead to blindness in patients with diabetic retinopathy
- Diagnos Inc. is up 3.03 percent, trading at $0.17 at 10:47 a.m. ET
Diagnos (ADK) is launching the testing phase for autonomous artificial intelligence solutions dedicated to diabetic retinopathy screening.
The Quebec-based company is working in partnership with the Centre hospitalier de l’Université de Montréal (CHUM).
The study aims to make it possible to “establish, with precision, the level of performance of the autonomous algorithms utilized for the identification of the disease and its classification by level of severity, with patients suffering from diabetic retinopathy.”
This marks the final step of the partnership, which began in 2018.
“This stage of testing and performance analysis was approved by the CHUM, following the positive results obtained over the past few months by CHUM clinicians as part of the rigorous independent evaluation process applied to analyze the performance of the classification algorithms by level of severity run in autonomous mode,” said DIAGNOS President Andrré Larente.
Retinal images of more than 600 diabetic patients from the CHUM’s endocrinology department will be analyzed by the NeoRetina artificial intelligence algorithm of deep learning from DIAGNOS.
The hope is to eventually be able to reduce complications that can lead to blindness in patients with diabetic retinopathy.
“This project is well aligned with the CHUM’s desire to improve accessibility of its services to the patients through partnerships that nurture the development and integration of innovative solutions.” said CHUM President and CEO Fabrice Brunet.
The test will allow the CHUM professionals to precisely establish the level of performance and precision of the NeoRetina autonomous algorithms.
Diagnos Inc. is up 3.03 percent, trading at $0.17 at 10:47 a.m. ET.